3 AI-Driven Medical Device Stocks to Watch in 2025

Generative and agentic AI are rapidly transforming the medical device sector, enhancing clinical workflows and patient care through applications like synthetic imaging, real-time documentation, autonomous decision-making, and AI-guided surgery. This accelerating adoption is driven by the demand for precision medicine and a favorable regulatory environment, evidenced by over 700 FDA-approved AI-enabled devices. Consequently, Boston Scientific (BSX), Johnson & Johnson (JNJ), and GE HealthCare (GEHC) are identified as key players poised for strong performance in 2025, leveraging their significant AI investments and innovative product integrations, such as BSX's HeartLogic and JNJ's Ottava, alongside favorable financial projections.

Analysis

The medical device sector is experiencing a significant technological shift driven by the integration of generative and agentic AI, a trend supported by strong clinical demand for precision medicine and a favorable regulatory environment. The U.S. FDA has accelerated this adoption, with over 700 AI-enabled devices now approved, a tenfold increase since 2020. Within this landscape, Boston Scientific (BSX) is positioned for aggressive growth, with projected 2025 sales and earnings growth of 16.4% and 15.9% respectively, far surpassing the industry's flat growth forecast. This is underpinned by a robust cash flow rate of 26.5% and specific AI-driven products like HeartLogic. Johnson & Johnson (JNJ) demonstrates strong fundamentals through its MedTech division, leveraging AI in its Ottava robotics platform; while its projected sales growth is a more modest 2.8%, its 24.4% net margin significantly outperforms the industry's 18.6%. GE HealthCare (GEHC) stands out as a leader in regulatory milestones, having secured 80 FDA clearances for AI-enabled devices. Despite a more conservative projected sales growth of 3.2%, its strong cash flow of 9.7% and focus on AI in precision care solidify its key role in the industry's evolution.

Key Decisions for Investors

• Given its projected 16.4% sales growth and superior cash flow, investors may view Boston Scientific (BSX) as a primary growth-oriented investment to gain exposure to the AI-MedTech theme.
• For a more defensive exposure, Johnson & Johnson (JNJ) offers a combination of AI innovation with strong profitability, evidenced by its 24.4% net margin, making it suitable for investors prioritizing stability.
• GE HealthCare (GEHC) warrants a 'watch-list' position; investors should monitor if its leadership in AI device approvals can translate into financial performance that outpaces its current 3.2% sales growth projection.
• Consider that the flat industry growth backdrop favors well-capitalized innovators, suggesting a strategy of overweighting firms like BSX and JNJ that demonstrate clear financial benefits from their AI investments.